This is a phase II, single-group pilot study to evaluate efficacy and pharmacokinetics. This study's overarching aim is to evaluate the systemic effects of black raspberries in patients with myelodysplastic syndrome. Twenty-one patients with MDS will be treated with 25 gm (2x/day) of BRB powder taken orally.